198 related articles for article (PubMed ID: 29396434)
1. Cooperation between Hsp90 and mortalin/GRP75 in resistance to cell death induced by complement C5b-9.
Rozenberg P; Ziporen L; Gancz D; Saar-Ray M; Fishelson Z
Cell Death Dis; 2018 Feb; 9(2):150. PubMed ID: 29396434
[TBL] [Abstract][Full Text] [Related]
2. Mortalin/GRP75 binds to complement C9 and plays a role in resistance to complement-dependent cytotoxicity.
Saar Ray M; Moskovich O; Iosefson O; Fishelson Z
J Biol Chem; 2014 May; 289(21):15014-22. PubMed ID: 24719326
[TBL] [Abstract][Full Text] [Related]
3. Complement triggers relocation of Mortalin/GRP75 from mitochondria to the plasma membrane.
Mazkereth N; Rocca F; Schubert JR; Geisler C; Hillman Y; Egner A; Fishelson Z
Immunobiology; 2016 Dec; 221(12):1395-1406. PubMed ID: 27475989
[TBL] [Abstract][Full Text] [Related]
4. Regulation of Complement-Dependent Cytotoxicity by MicroRNAs miR-200b, miR-200c, and miR-217.
Hillman Y; Mazkereth N; Farberov L; Shomron N; Fishelson Z
J Immunol; 2016 Jun; 196(12):5156-65. PubMed ID: 27183614
[TBL] [Abstract][Full Text] [Related]
5. Mortalin/GRP75 promotes release of membrane vesicles from immune attacked cells and protection from complement-mediated lysis.
Pilzer D; Fishelson Z
Int Immunol; 2005 Sep; 17(9):1239-48. PubMed ID: 16091382
[TBL] [Abstract][Full Text] [Related]
6. Mortalin inhibitors sensitize K562 leukemia cells to complement-dependent cytotoxicity.
Pilzer D; Saar M; Koya K; Fishelson Z
Int J Cancer; 2010 Mar; 126(6):1428-35. PubMed ID: 19739077
[TBL] [Abstract][Full Text] [Related]
7. Complement C5b-9 and Cancer: Mechanisms of Cell Damage, Cancer Counteractions, and Approaches for Intervention.
Fishelson Z; Kirschfink M
Front Immunol; 2019; 10():752. PubMed ID: 31024572
[TBL] [Abstract][Full Text] [Related]
8. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9.
Rollins SA; Sims PJ
J Immunol; 1990 May; 144(9):3478-83. PubMed ID: 1691760
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9.
Rollins SA; Zhao J; Ninomiya H; Sims PJ
J Immunol; 1991 Apr; 146(7):2345-51. PubMed ID: 1706395
[TBL] [Abstract][Full Text] [Related]
10. Mortalin peptides exert antitumor activities and act as adjuvants to antibody-mediated complement-dependent cytotoxicity.
Jubran R; Saar-Ray M; Wawruszak A; Ziporen L; Donin N; Bairey O; Fishelson Z
Int J Oncol; 2020 Oct; 57(4):1013-1026. PubMed ID: 32700755
[TBL] [Abstract][Full Text] [Related]
11. Hsp90 inhibitor geldanamycin attenuates the cytotoxicity of sunitinib in cardiomyocytes via inhibition of the autophagy pathway.
Kimura T; Uesugi M; Takase K; Miyamoto N; Sawada K
Toxicol Appl Pharmacol; 2017 Aug; 329():282-292. PubMed ID: 28624441
[TBL] [Abstract][Full Text] [Related]
12. Quantification of complement C5b-9 binding to cells by flow cytometry.
Moskovich O; Fishelson Z
Methods Mol Biol; 2014; 1100():103-8. PubMed ID: 24218253
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic heat shock protein 70 induction confers cytoprotection against inflammation in gliovascular cells.
Kacimi R; Yenari MA
Glia; 2015 Jul; 63(7):1200-12. PubMed ID: 25802219
[TBL] [Abstract][Full Text] [Related]
14. Potent inhibition of terminal complement assembly by clusterin: characterization of its impact on C9 polymerization.
McDonald JF; Nelsestuen GL
Biochemistry; 1997 Jun; 36(24):7464-73. PubMed ID: 9200695
[TBL] [Abstract][Full Text] [Related]
15. Vitronectin-mediated inhibition of complement: evidence for different binding sites for C5b-7 and C9.
Milis L; Morris CA; Sheehan MC; Charlesworth JA; Pussell BA
Clin Exp Immunol; 1993 Apr; 92(1):114-9. PubMed ID: 7682159
[TBL] [Abstract][Full Text] [Related]
16. HSP90 modulates actin dynamics: inhibition of HSP90 leads to decreased cell motility and impairs invasion.
Taiyab A; Rao ChM
Biochim Biophys Acta; 2011 Jan; 1813(1):213-21. PubMed ID: 20883729
[TBL] [Abstract][Full Text] [Related]
17. CD59 blocks not only the insertion of C9 into MAC but inhibits ion channel formation by homologous C5b-8 as well as C5b-9.
Farkas I; Baranyi L; Ishikawa Y; Okada N; Bohata C; Budai D; Fukuda A; Imai M; Okada H
J Physiol; 2002 Mar; 539(Pt 2):537-45. PubMed ID: 11882685
[TBL] [Abstract][Full Text] [Related]
18. Hexamerization-enhanced CD20 antibody mediates complement-dependent cytotoxicity in serum genetically deficient in C9.
Taylor RP; Lindorfer MA; Cook EM; Beurskens FJ; Schuurman J; Parren PWHI; Zent CS; VanDerMeid KR; Burack R; Mizuno M; Morgan BP
Clin Immunol; 2017 Aug; 181():24-28. PubMed ID: 28578024
[TBL] [Abstract][Full Text] [Related]
19. A synthetic peptide from complement protein C9 binds to CD59 and enhances lysis of human erythrocytes by C5b-9.
Tomlinson S; Whitlow MB; Nussenzweig V
J Immunol; 1994 Feb; 152(4):1927-34. PubMed ID: 7509832
[TBL] [Abstract][Full Text] [Related]
20. Radicicol but not geldanamycin evokes oxidative stress response and efflux protein inhibition in ARPE-19 human retinal pigment epithelial cells.
Ryhänen T; Mannermaa E; Oksala N; Viiri J; Paimela T; Salminen A; Atalay M; Kaarniranta K
Eur J Pharmacol; 2008 Apr; 584(2-3):229-36. PubMed ID: 18313664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
